Expect More Use of the Antibiotics Avycaz or Vabomere for "CRE"

October 2018

You'll hear continued debate about which antibiotics to use to treat carbapenem-resistant Enterobacteriaceae (CRE) infections.

Work with ID to tailor regimens based on susceptibility and safety.

Newer antibiotics. Anticipate using ceftazidime/avibactam (Avycaz) or meropenem/vaborbactam (Vabomere) more. Recent evidence suggests they are safer and may be more effective than traditional options...such as meropenem PLUS a polymyxin (colistin, etc).

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Antibiotics Expect More Use of the Antibiotics Avycaz or Vabomere for "CRE"
Hematology & Oncology Watch for Autoimmune-Like Effects From Cancer Immunotherapy
Influenza Encourage Patients to Get Vaccinated Now for the 2018-2019 Influenza Season
Pediatrics Incorporate Specific Steps to Reduce Pediatric Med Errors
Antipsychotics Watch for Errors With Long-Acting Injectable Antipsychotics
Cardiology Suggest Screening Post-MI Patients for Depression at Follow-Up Appointments
HIV & AIDS Expect Integrase Inhibitors to Gain an Edge in Treating HIV
Pregnancy Help Colleagues Decipher FDA's New Med Safety in Pregnancy Ratings
Dermatology Get to the Bottom of Diaper Rash in Adults and Kids
Pharmacogenetics Be Aware of the Role of Pharmacogenetic Testing for Mental Health Conditions
New Drugs Stay Alert for the New Endometriosis Med, Elagolix (Orilissa)
Ensure Safe Use if Your Hospital Allows Essential Oils